|Salary:||Competitive with benefits, subject to skills and experience|
|Placed On:||4th May 2021|
|Closes:||28th May 2021|
Location: The Francis Crick Institute, Midland Road, London
Genetic studies in Crohn’s disease and ulcerative colitis (collectively termed inflammatory bowel disease or IBD) have been incredibly successful, but the pathogenic mechanisms at disease-associated loci remain largely unknown.
We have developed a series of complementary methods to study the underlying biology, including scalable methods to functionally resolve causal variants, CRISPR-based approaches to establish the physiological role(s) of associated loci, and in vitro and in vivo assays of immune cell function to determine the pathological consequences. The successful applicant will use these – and other methods – to help resolve disease mechanisms at uncharacterised genetic loci that have biological activity in subsets of primary CD4 T cells. There will be a possibility of extending this work into other cell-types, and/or identifying small molecule modulators of any identified pathways.
For more information, see https://www.crick.ac.uk/research/labs/james-lee or for an example of related work, see Bourges et al. Resolving mechanisms of immune‐mediated disease in primary CD4 T cells. EMBO Molecular Medicine 2020. https://www.embopress.org/doi/full/10.15252/emmm.202012112
Informal enquiries are welcome, and should be directed to James Lee (email@example.com).
We are seeking a talented postdoctoral researcher to help uncover the biological mechanisms by which genetic variants predispose to inflammatory bowel disease (IBD). The successful applicant will join the Genetic Mechanisms of Disease lab, led by James Lee, at the Francis Crick Institute - a pioneering biomedical research institute dedicated to innovation and science.
The Lee lab, which is relocating from the University of Cambridge in July 2021, studies the pathogenesis of immune-mediated and inflammatory diseases using genetics, genomics, molecular biology, and CRISPR-based approaches (all in primary immune cells). Our goal is not only to resolve the pathways involved, but to identify therapeutic opportunities that could lead to better treatments.
The Francis Crick Institute is a biomedical discovery institute dedicated to understanding the fundamental biology underlying health and disease. Its work is helping to understand why disease develops and to translate discoveries into new ways to prevent, diagnose and treat illnesses such as cancer, heart disease, stroke, infections, and neurodegenerative diseases.
An independent organisation, its founding partners are the Medical Research Council (MRC), Cancer Research UK, Wellcome, UCL (University College London), Imperial College London and King’s College London.
The Crick was formed in 2015, and in 2016 it moved into a new state-of-the-art building in central London which brings together 1500 scientists and support staff working collaboratively across disciplines, making it the biggest biomedical research facility under in one building in Europe.
The Francis Crick Institute will be world-class with a strong national role. Its distinctive vision for excellence includes commitments to collaboration; developing emerging talent and exporting it the rest of the UK; public engagement; and helping turn discoveries into treatments as quickly as possible to improve lives and strengthen the economy.
Type / Role: